FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Acute Adenoviral Conjunctivitis
Interventions
DRUG

FST-100 Ophthalmic Suspension

FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.

DRUG

Placebo

A regimen of 2 drops 4 times a day while awake for 5 days.

Trial Locations (13)

10003

Ophthalmic Consultants PC The New York Eye and Ear Infirmary, New York

11793

Wantagh

28204

Charlotte

33176

The Center for Excellence in Eye, Miami

33179

Ocean Ophthalmology, North Miami Beach

43213

Columbus Ophthalmology Associates, Columbus

60016

The Midwest Center for Sight, Des Plaines

60169

Hoffman Estates

64133

Silverstein Eye Centers, Kansas City

65804

St. Johns Clinic, Springfield

80907

Colorado Eye Associates, Colorado Springs

90505

Wolstan and Goldberg Eye Associates, Torrance

06518

Eye Center, Hamden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT00941486 - FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis | Biotech Hunter | Biotech Hunter